Related Experiment Video
Updated: Jun 25, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Mycoplasma pneumoniae Outbreak in 2023: Post-pandemic Resurgence of an Atypical Bacterial Pathogen
Pallavi Upadhyay1, Vijay Singh1
1Research & Development (R&D), HealthTrackRX, Denton, USA.
Abstract:
The syndromic nature of infections caused by pneumonia-causing pathogens including Mycoplasma pneumoniae necessitates detection via multiplex PCR for accurate and timely diagnosis to control the infection spread. In this study, we demonstrate an increase in the detection of M. pneumoniae in the outpatient population, during 2023, as compared to the previous two years (2021-2022). In this aggregated survey, respiratory samples collected within the continental United States were tested for the presence of M. pneumoniae and other respiratory bacterial and viral pathogens using a multiplex PCR assay. Patient data was analyzed on the basis of age, gender and geographical location. The positive detection of M. pneumoniae in 2021 and 2022 was 0.004% and 0.006%, respectively. The positivity rate of M. pneumoniae in 2023 increased to 0.21%. The highest proportion of M. pneumoniae cases were detected from Georgia with the outbreak generally concentrated in large urban settings. Median age of the patients testing positive for M. pneumoniae was 10 (interquartile range [IQR] 8-18) years with an almost equal distribution between male and female patients. Other respiratory, viral and bacterial, pathogens detected in samples positive for M. pneumoniae were similar in proportion to the M. pneumonia-negative population. A survey of the ICD-10 codes submitted in conjunction with the samples suggests that the current outbreak is mostly associated with upper respiratory tract infections. The present study is the first detailed report in the United States that shows an unprecedented increase in the detection of M. pneumoniae in the outpatient population during 2023. Our analysis suggests that this outbreak was not associated with any other bacterial or viral respiratory pathogen. The outbreak of this atypical pathogen was concentrated in the pediatric population in large urban areas. The 2023 outbreak could be a return of the cyclical M. pneumoniae outbreaks witnessed prior to the COVID-19 pandemic. Our study highlights the importance of performing continuous surveillance of respiratory pathogens, especially in the altered epidemiological landscape of the post-COVID world.
Insights
Mycoplasma pneumoniae infections significantly increased in US outpatients in 2023, particularly in children in urban areas. This rise in M. pneumoniae cases highlights the need for ongoing respiratory pathogen surveillance.
Area of Science:
- Clinical microbiology and infectious diseases
- Epidemiology of respiratory pathogens
- Public health surveillance
Background:
- Mycoplasma pneumoniae is a common cause of respiratory infections, often presenting with syndromic symptoms.
- Accurate and timely diagnosis using multiplex PCR is crucial for controlling the spread of M. pneumoniae.
- Previous M. pneumoniae outbreaks have followed cyclical patterns, with a notable absence during the COVID-19 pandemic.
Purpose of the Study:
- To report the detection rates of M. pneumoniae in the US outpatient population during 2023 compared to 2021-2022.
- To analyze demographic and geographic factors associated with M. pneumoniae infections.
- To investigate the co-occurrence of M. pneumoniae with other respiratory pathogens and associated diagnoses.
Main Methods:
- An aggregated survey of respiratory samples from the continental US was analyzed using multiplex PCR.
- Samples were tested for M. pneumoniae and other bacterial and viral respiratory pathogens.
- Patient data, including age, gender, and geographical location, were analyzed alongside ICD-10 codes.
Main Results:
- M. pneumoniae detection increased from 0.004% (2021) and 0.006% (2022) to 0.21% in 2023.
- The highest proportion of cases were detected in Georgia, concentrated in large urban settings, primarily affecting children (median age 10 years).
- M. pneumoniae infections were mainly associated with upper respiratory tract infections and not significantly linked to other detected pathogens.
Conclusions:
- The study reports an unprecedented increase in M. pneumoniae detection in US outpatients in 2023, particularly in pediatric populations in urban areas.
- This outbreak appears isolated, without significant co-infection with other common respiratory pathogens.
- The findings suggest a potential return of cyclical M. pneumoniae outbreaks and underscore the importance of continuous respiratory pathogen surveillance.
More Related Videos
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

